23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Palvella Therapeutics, Inc. › 2025-2026

Palvella Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Palvella Therapeutics, Inc.’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 8Reported items
  • 195Asset managers, any item
  • 1,843Fund votes
  • June 10, 2026Meeting date

Results at a glance

Meeting of June 10, 2026: 7 items on Palvella Therapeutics, Inc.’s Form 8-K, filed June 16, 2026: 3 approved · 4 passed (calculated).

Dissent

Notable dissent: 1 director (18.2% against); 2 other board items (24.8%, 24.3% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2025-2026

Explore Palvella Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Palvella Therapeutics, Inc.

These tallies are Palvella Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Palvella Therapeutics, Inc. — official shareholder meeting results, meeting held June 10, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: George M. Jenkins 9,907,220---- 268,8341,401,415 97%Passed (calculated)—
Elect Director: Todd C. Davis 8,321,303---- 1,854,7511,401,415 82%Passed (calculated)—
Elect Director: John Doux, M.D. 9,958,528---- 217,5261,401,415 98%Passed (calculated)—
2. Ratification of Independent Registered Public Accountant 11,557,68713,2166,566 ---- 99.9%Approved—
3. Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2025 10,008,180160,7177,157 --1,401,415 98%Approved—
5. Approval of an amendment to the Palvella Therapeutics, Inc 7,692,7092,475,4707,875 --1,401,415 76%Approved—
6. Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5 7,649,2432,519,0687,743 --1,401,415 75%Passed (calculated)—

Source: Palvella Therapeutics, Inc., Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.

How asset managers voted at the Palvella Therapeutics, Inc. 2025-2026 meeting

195 asset managers disclosed a vote on at least one Palvella Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Palvella Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: George M. Jenkins

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 9,907,220WITHHELD: 268,834
Details: description as filed, official tally, votes by 61 asset managers

Description as filed by funds: Election of three director nominees to serve as Class III directors whose term will expire in 2029: George M. Jenkins

Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: George M. Jenkins”): 9,907,220 for, 268,834 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 2,899,920 for, 113,110 withheld.

FOR
FOR: 2,899,920WITHHOLD: 113,110
Largest asset managers voting on “Election of three director nominees to serve as Class III directors whose term will expire in 2029: George M. ” at Palvella Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard562,1680 0422For
Federated Hermes408,2150 00For
T. Rowe Price306,9330 00For
State Street292,9350 00For
MUTUAL FUND SERIES TRUST231,4840 00For
BlackRock194,2780 00For
PRIMECAP Odyssey Funds163,4750 00For
AllianceBernstein137,1450 00For
Prudential/PGIM109,2050 00For
Principal31,9610 039,911Mixed
RBB FUND, INC.00 065,909Withhold
Legg Mason56,4800 00For
Fidelity44,9450 00For
Calamos33,0710 00For
Royce31,5000 00For
Neuberger Berman24,1530 00For
Invesco23,6290 00For
Charles Schwab22,9550 00For
Jackson National20,7570 00For
TIAA19,6640 00For
Equitable19,5640 00For
CARILLON SERIES TRUST15,3530 00For
Advisors' Inner Circle Fund III12,3710 00For
Victory Capital11,4030 00For
ALPS ETF Trust11,1320 00For

Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).

Elect Director: John Doux, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 9,958,528WITHHELD: 217,526
Details: description as filed, official tally, votes by 61 asset managers

Description as filed by funds: Election of three director nominees to serve as Class III directors whose term will expire in 2029: John Doux, M.D.

Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: John Doux, M.D.”): 9,958,528 for, 217,526 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 2,901,140 for, 111,890 withheld.

FOR
FOR: 2,901,140WITHHOLD: 111,890
Largest asset managers voting on “Election of three director nominees to serve as Class III directors whose term will expire in 2029: John Doux,” at Palvella Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard562,5900 00For
Federated Hermes408,2150 00For
T. Rowe Price306,9330 00For
State Street292,9350 00For
MUTUAL FUND SERIES TRUST231,4840 00For
BlackRock194,2780 00For
PRIMECAP Odyssey Funds163,4750 00For
AllianceBernstein137,1450 00For
Prudential/PGIM109,2050 00For
Principal31,9610 039,911Mixed
RBB FUND, INC.00 065,909Withhold
Legg Mason56,4800 00For
Fidelity44,9450 00For
Calamos33,0710 00For
Royce31,5000 00For
Neuberger Berman24,1530 00For
Invesco23,6290 00For
Charles Schwab22,9550 00For
Jackson National20,7570 00For
TIAA19,6640 00For
Equitable19,5640 00For
CARILLON SERIES TRUST15,3530 00For
Advisors' Inner Circle Fund III12,3710 00For
Victory Capital11,4030 00For
ALPS ETF Trust11,1320 00For

Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).

Elect Director: Todd C. Davis

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD
FOR: 8,321,303WITHHELD: 1,854,751
Details: description as filed, official tally, votes by 61 asset managers

Description as filed by funds: Election of three director nominees to serve as Class III directors whose term will expire in 2029: Todd C. Davis

Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: Todd C. Davis”): 8,321,303 for, 1,854,751 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 1,826,990 for, 1,186,036 withheld, 4 abstained.

FORWITHHOLD
FOR: 1,826,990ABSTAIN: 4WITHHOLD: 1,186,036
Largest asset managers voting on “Election of three director nominees to serve as Class III directors whose term will expire in 2029: Todd C. Da” at Palvella Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard562,1640 4422For
Federated Hermes00 0408,215Withhold
T. Rowe Price306,9330 00For
State Street6000 0292,335Withhold
MUTUAL FUND SERIES TRUST231,4840 00For
BlackRock194,2780 00For
PRIMECAP Odyssey Funds163,4750 00For
AllianceBernstein00 0137,145Withhold
Prudential/PGIM109,2050 00For
Principal00 071,872Withhold
RBB FUND, INC.00 065,909Withhold
Legg Mason56,4800 00For
Fidelity17,8320 027,113Mixed
Calamos33,0710 00For
Royce00 031,500Withhold
Neuberger Berman00 024,153Withhold
Invesco23,6290 00For
Charles Schwab22,9550 00For
Jackson National20,7570 00For
TIAA00 019,664Withhold
Equitable14,7040 04,860Mixed
CARILLON SERIES TRUST00 015,353Withhold
Advisors' Inner Circle Fund III12,3710 00For
Victory Capital00 011,403Withhold
ALPS ETF Trust00 011,132Withhold

Showing the 25 largest of 61 asset managers. All 61 are in the interactive database (link above).

Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to…

Calculated outcomeCORPORATE GOVERNANCEPassed (calculated)

75% Majority: yes · of votes cast

FOR 75%AGAINST
FOR: 7,649,243AGAINST: 2,519,068
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEETING TO APPROVE PROPOSAL 5.

Palvella Therapeutics, Inc.’s own tally for this item (“6. Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5”): 7,649,243 for, 2,519,068 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 1,571,298 for, 1,434,082 against, 6,070 abstained.

FORAGAINST
FOR: 1,571,298AGAINST: 1,434,082ABSTAIN: 6,070
Largest asset managers voting on “APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEET” at Palvella Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard92,451470,139 00Mixed
Federated Hermes408,2150 00For
T. Rowe Price0306,933 00Against
State Street600292,335 00Against
MUTUAL FUND SERIES TRUST231,4840 00For
BlackRock194,2780 00For
PRIMECAP Odyssey Funds163,4750 00For
AllianceBernstein137,1450 00For
Prudential/PGIM109,2050 00For
Principal71,364508 00For
RBB FUND, INC.65,9090 00For
Legg Mason056,480 00Against
Fidelity4,40640,539 00Mixed
Calamos33,0710 00For
Royce031,500 00Against
Neuberger Berman024,153 00Against
Invesco23,6290 00For
Charles Schwab022,955 00Against
Jackson National020,757 00Against
TIAA019,664 00Against
Equitable17,2892,275 00Mixed
CARILLON SERIES TRUST015,353 00Against
Advisors' Inner Circle Fund III7,0115,360 00Mixed
Victory Capital011,403 00Against
ALPS ETF Trust011,132 00Against

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Approval of an amendment to the 2024 equity incentive plan to increase the authorized shares issuable under the 2024…

66% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST
Details: description as filed, votes by 63 asset managers

Description as filed by funds: APPROVAL OF AN AMENDMENT TO THE 2024 EQUITY INCENTIVE PLAN TO INCREASE THE AUTHORIZED SHARES ISSUABLE UNDER THE 2024 PLAN BY 750,000 SHARES.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 60 asset managers voting on “APPROVAL OF AN AMENDMENT TO THE 2024 EQUITY INCENTIVE PLAN TO INCREASE THE AUTHORIZED SHARES ISSUABLE UNDER TH” at Palvella Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard91,586471,004 00Mixed
Federated Hermes408,2150 00For
T. Rowe Price306,9330 00For
State Street132292,803 00Against
MUTUAL FUND SERIES TRUST231,4840 00For
BlackRock194,2780 00For
PRIMECAP Odyssey Funds163,4750 00For
AllianceBernstein0137,145 00Against
Prudential/PGIM109,2050 00For
Principal39,91131,961 00Mixed
RBB FUND, INC.65,9090 00For
Legg Mason056,480 00Against
Fidelity4,40640,539 00Mixed
Calamos33,0710 00For
Royce031,500 00Against
Neuberger Berman024,153 00Against
Invesco023,629 00Against
Charles Schwab022,955 00Against
Jackson National020,757 00Against
TIAA19,6640 00For
Equitable14,7044,860 00Mixed
CARILLON SERIES TRUST015,353 00Against
Advisors' Inner Circle Fund III012,371 00Against
Victory Capital011,403 00Against
ALPS ETF Trust011,132 00Against

Fund voting reports, all 60 managers: 1,706,735 for, 1,298,644 against, 6,070 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “APPROVAL OF AN AMENDMENT TO THE 2024 EQUITY INCENTIVE PLAN TO INCREASE THE AUTHORIZED SHARES ISSUABLE UNDER TH” at Palvella Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
First Light Asset Management, LLC750,9080 00For
APIS CAPITAL ADVISORS, LLC50,0000 00For
Vident Advisory, LLC0153 00Against

Institutional-manager reports, all 3 managers: 800,908 for, 153 against.

Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2025

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 10,008,180AGAINST: 160,717
Details: description as filed, official tally, votes by 195 asset managers

Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Palvella Therapeutics, Inc.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2025”): 10,008,180 for, 160,717 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers in 2025, as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 61 asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Palvella Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard562,5900 00For
Federated Hermes408,2150 00For
T. Rowe Price306,9330 00For
State Street292,818117 00For
MUTUAL FUND SERIES TRUST231,4840 00For
BlackRock194,2780 00For
PRIMECAP Odyssey Funds163,4750 00For
AllianceBernstein137,1450 00For
Prudential/PGIM109,2050 00For
Principal71,8720 00For
RBB FUND, INC.65,9090 00For
Legg Mason56,4800 00For
Fidelity44,9450 00For
Calamos33,0710 00For
Royce31,5000 00For
Neuberger Berman24,1530 00For
Invesco023,629 00Against
Charles Schwab22,9550 00For
Jackson National20,7570 00For
TIAA19,6640 00For
Equitable19,5640 00For
CARILLON SERIES TRUST15,3530 00For
Advisors' Inner Circle Fund III12,3710 00For
Victory Capital11,4030 00For
ALPS ETF Trust11,1320 00For

Fund voting reports, all 61 managers: 2,956,351 for, 50,608 against, 6,070 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 150 asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at Palvella Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
MONTANOVA CAPITAL, LLC1,173,3660 00For
BVF INC/IL960,9890 00For
Frazier Life Sciences Management, L.P.882,4000 00For
First Light Asset Management, LLC750,9080 00For
State Street407,6301,939 00For
Federated Hermes408,2150 00For
T. Rowe Price388,3830 00For
JENNISON ASSOCIATES LLC275,465712 00For
Siren, L.L.C.247,1920 00For
AllianceBernstein228,8200 00For
PRIMECAP MANAGEMENT CO/CA/195,2300 00For
FRONTIER CAPITAL MANAGEMENT CO LLC156,3675,681 00For
Woodline Partners LP148,2160 00For
ORBIMED ADVISORS LLC123,6430 00For
MPM BioImpact LLC117,8060 00For
Artisan102,7030 00For
BlackRock98,433421 00For
EMERALD ADVISERS, LLC87,3990 00For
Aberdeen81,0810 00For
Vanguard80,0130 00For
Clearbridge Investments, LLC59,3450 00For
Neuberger Berman52,5800 00For
APIS CAPITAL ADVISORS, LLC50,0000 00For
Avidity Partners Management LP49,2750 00For
EMERALD MUTUAL FUND ADVISERS TRUST39,9110 00For

Institutional-manager reports, all 150 managers: 7,728,872 for, 111,301 against, 68 abstained, 1,385 1 year. Showing the 25 largest; every one is in the interactive database (link above).

Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99.9% Fund and manager reports combined; may count the same shares twice · no official result

FOR1 YEAR
Details: description as filed, votes by 190 asset managers

Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 60 asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID T” at Palvella Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
Federated Hermes00 00--
T. Rowe Price00 00--
State Street00 00--
MUTUAL FUND SERIES TRUST00 00--
BlackRock00 00--
PRIMECAP Odyssey Funds00 00--
AllianceBernstein00 00--
Prudential/PGIM00 00--
Principal00 00--
RBB FUND, INC.00 00--
Legg Mason00 00--
Fidelity00 00--
Calamos00 00--
Royce00 00--
Neuberger Berman00 00--
Invesco00 00--
Charles Schwab00 00--
Jackson National00 00--
TIAA00 00--
Equitable00 00--
CARILLON SERIES TRUST00 00--
Advisors' Inner Circle Fund III00 00--
Victory Capital00 00--
ALPS ETF Trust00 00--

Fund voting reports, all 60 managers: 15,008 for, 6,070 abstained, 2,990,133 1 year, 218 3 year, 21 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 145 asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID T” at Palvella Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
MONTANOVA CAPITAL, LLC00 00--
BVF INC/IL00 00--
Frazier Life Sciences Management, L.P.882,4000 00For
First Light Asset Management, LLC750,9080 00For
State Street00 00--
Federated Hermes00 00--
T. Rowe Price00 00--
JENNISON ASSOCIATES LLC00 00--
Siren, L.L.C.00 00--
AllianceBernstein00 00--
PRIMECAP MANAGEMENT CO/CA/00 00--
FRONTIER CAPITAL MANAGEMENT CO LLC00 00--
Woodline Partners LP00 00--
ORBIMED ADVISORS LLC00 00--
MPM BioImpact LLC00 00--
Artisan00 00--
BlackRock00 00--
EMERALD ADVISERS, LLC00 00--
Aberdeen00 00--
Vanguard00 00--
Clearbridge Investments, LLC00 00--
Neuberger Berman00 00--
APIS CAPITAL ADVISORS, LLC50,0000 00For
Avidity Partners Management LP00 00--
EMERALD MUTUAL FUND ADVISERS TRUST00 00--

Institutional-manager reports, all 145 managers: 1,684,983 for, 35 against, 6,116,064 1 year, 39,288 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Independent Registered Public Accountant

Official resultAUDIT-RELATEDReported outcome: Approved

99.9% Approved · of votes cast

FOR 99.9%
FOR: 11,557,687AGAINST: 13,216

Prior year: 99.9% for (June 10, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE 2026 FISCAL YEAR.

Palvella Therapeutics, Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accountant”): 11,557,687 for, 13,216 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The appointment of Ernst &Young LLP as the Company's independent registered public accounting firm for the 2026 fiscal year was ratified, as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 3,005,368 for, 12 against, 6,070 abstained.

FOR
FOR: 3,005,368AGAINST: 12ABSTAIN: 6,070
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIR” at Palvella Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard562,5900 00For
Federated Hermes408,2150 00For
T. Rowe Price306,9330 00For
State Street292,92312 00For
MUTUAL FUND SERIES TRUST231,4840 00For
BlackRock194,2780 00For
PRIMECAP Odyssey Funds163,4750 00For
AllianceBernstein137,1450 00For
Prudential/PGIM109,2050 00For
Principal71,8720 00For
RBB FUND, INC.65,9090 00For
Legg Mason56,4800 00For
Fidelity44,9450 00For
Calamos33,0710 00For
Royce31,5000 00For
Neuberger Berman24,1530 00For
Invesco23,6290 00For
Charles Schwab22,9550 00For
Jackson National20,7570 00For
TIAA19,6640 00For
Equitable19,5640 00For
CARILLON SERIES TRUST15,3530 00For
Advisors' Inner Circle Fund III12,3710 00For
Victory Capital11,4030 00For
ALPS ETF Trust11,1320 00For

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Largest Palvella Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 14,313,659 shares outstanding at the time of that meeting.

Fund voting reports: top Palvella Therapeutics, Inc. shareholders by shares voted on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 3.93%
2Federated Hermes 2.85%
3T. Rowe Price 2.14%
4State Street 2.05%
5MUTUAL FUND SERIES TRUST 1.62%
6BlackRock 1.36%
7PRIMECAP Odyssey Funds 1.14%
8AllianceBernstein 0.96%
9Prudential/PGIM 0.76%
10Principal 0.50%
Institutional-manager reports: top Palvella Therapeutics, Inc. shareholders by shares voted on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.”, 2025-2026
#Asset manager % of shares outstanding
1MONTANOVA CAPITAL, LLC 8.20%
2BVF INC/IL 6.71%
3Frazier Life Sciences Management, L.P. 6.16%
4First Light Asset Management, LLC 5.25%
5State Street 2.86%
6Federated Hermes 2.85%
7T. Rowe Price 2.71%
8JENNISON ASSOCIATES LLC 1.93%
9Siren, L.L.C. 1.73%
10AllianceBernstein 1.60%

Reported Palvella Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Palvella Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Wesley H. Kaupinen1,128,685 7.89%Proxy statement (DEF 14A), table as of April 13, 2026
PRUDENTIAL FINANCIAL INC962,374 6.72%Schedule 13G, filed August 10, 2026
Jennison Associates LLC960,619 6.71%Schedule 13G, filed August 3, 2026
Entities affiliated with First Light Asset Management, LLC887,031 6.20%Proxy statement (DEF 14A), table as of April 13, 2026
Entities affiliated with Biotechnology Value Fund, L.P.879,009 6.14%Proxy statement (DEF 14A), table as of April 13, 2026
Entities affiliated with Suvretta Capital Management, LLC822,400 5.75%Proxy statement (DEF 14A), table as of April 13, 2026
Entities affiliated with Frazier Life Sciences Public Fund, L.P.722,400 5.05%Proxy statement (DEF 14A), table as of April 13, 2026
Frazier Life Sciences Public Fund, L.P.706,360 4.93%Schedule 13G, filed February 13, 2026
BlackRock686,853 4.80%Form 13F, quarter ended March 31, 2026
BVF PARTNERS L P/IL672,789 4.70%Schedule 13G, filed August 14, 2026

Percentages above are of 14,313,659 shares outstanding, as reported by Palvella Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Palvella Therapeutics, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 195 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,843 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. — Palvella Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Palvella Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Palvella Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Palvella Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Palvella Therapeutics (PVLA) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/palvella-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.